Biogen arms itself with impressive durability stats on Spinraza as Novartis’ rival gene therapy takes the field
Now 3 years into the market, Biogen has been able to count on its blockbuster Spinraza franchise as one of the few bright spots at the beleaguered biotech. But with Novartis’ newly approved gene therapy Zolgensma throwing some shade even there — researchers have been bolstering their case on spinal muscular atrophy with new data on the durability of their therapy.
Investigators turned up at the annual Cure SMA conference Monday to tout some truly breakthrough results for this drug, with all of the children on therapy able to sit upright and 88% walking without help.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
